Next Phase Newsletter

A venture capital firm with offices in Western Europe is currently making investments out of its newest fund that had an initial close recently. The firm looks to make equity investments into early stage companies up to €4M, with a focus on Seed to Series A investment rounds. The firm is actively reviewing new opportunities, with a focus in Europe. About 5-10% of the investments will be made in the US. 
 
With the newest fund, the firm is looking for technologies leveraging AI, digital therapeutics, and digital health platforms (i.e. data aggregation). The firm will consider medical device or diagnostics applications that have a AI component, but is most interested in investing in digital health. The firm is open to investing in companies in the earliest stages of development, pre-pilot. 
 
The firm is looking for privately held companies with experienced management teams. The firm is very open to working with incomplete management teams to help them fill out any gaps in management. The firm looks to be a strong value adding investor providing companies with its access to its network of other investors and strategic partners as well. The firm prefers to act as a lead or co-lead, especially in companies based in Spain, but will prefer to syndicate in opportunities outside of Europe. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An impact-driven venture fund with offices in US and Europe focuses on investments that improve the quality of Life and wellbeing of individuals and for medium and long-term relief of the ever-increasing strain on (public) healthcare, social welfare, and the planet. The firm invests in tech startups using Emerging & Disruptive Technologies (AI, Data, Blockchain, Iot,  AR/VR, and Digital Security) to solve social and environmental challenges within the 4 following SDGs: Health & Wellbeing, Quality Education, Sustainable City and Climate Action. The firm participates in Pre-Seed to Series A rounds with Seed being their sweet spot. The Fund invests across Europe. The firm also has an excellent coaching program to support its portfolio teams. 
 
In terms of Healthcare, the firm is interested in digital health software that helps with disease prevention, optimized recovery and improved quality of life. The firm purely invests in software and is not interested in hardware or devices. 
 
The firm does not have specific company requirements. The firm can act as a (co)lead investor and typically takes a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A global integrated business enterprise has a US-based, wholly owned subsidiary that is very interested in expanding the healthcare business and increasing its presence in the US. The firm seeks to make engage with early- and mid-stage healthcare companies through strategic investment, partnerships, and more. The firm is open to global opportunities.  
 
Within life sciences and healthcare sectors, the firm is most interested in medical devices, diagnostics, digital health, and healthcare services. Within medtech, the firm focuses on general surgery, laparoscopic surgery, orthopedics, OB/GYN, urology, GI, ENT, respiratory/anesthesia, radiology, and cardiology. In digital health, technologies addressing areas such as virtual care providers, wellness management, etc. that could benefit the aging population are of interest. The firm is can partner with companies across a wide stage of development, from companies still developing a prototype to those who are already on the market. The firm does not invest in biotech or pharmaceutical companies. 
 
The firm has no specific company or management team requirements. The firm is interested in companies who are looking to enter the Asian market, and can help support the companies in navigating regulatory hurdles by leveraging their own regulatory team. The firm can act as a lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A corporate venture capital firm that was launched within the last year was operating in stealth for the year prior. The firm prefers to invest in Series A, though can also invest in Seed and Series B if there is a great fit. The firm invest in pre-clinical stage and devices already with FDA approval. The firm is a hands-on investor, providing value and leverageable knowledge to the companies from both investor team and the corporation. The firm invests globally with a first ticket of €1-3M. 

 
The firm is largely focused on investing in diagnostics and digital solutions, as well as select life science tools. 
 
The firm prefers to syndicate with other VCs or CVCs, and typically requires a board seat as part of the  hands-on approach to the company. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An investment firm founded in 2015 invests in technology, medical, and science-related deals. The firm typically engages in late Seed and Series A financings with typical check size being around $2M. Though the firm’s first searches are in the Midwest US, they are open to all investment opportunities across the US – generally, the firm avoids Boston and Silicon Valley. The firm will lead about half of its investments. 
 
Within life sciences, the firm invests in all sectors but is currently focusing on therapeutics and diagnostics companies. The firm is generally indication-agnostic, but in terms of diagnostics, they are focusing on cancer. For therapeutics companies, the firm prefers them to be about a year before conducting human trials. For medical devices, diagnostics, and digital health, companies should be pre-revenue and pre-FDA approval. 
 
The firm does not require to take a board observer seat but may take one depending on the case. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A Biotech & Life Science strategic partner with a venture capital fund is currently investing from their second fund, which is roughly USD $50M and targeted to reach $100M. The firm typically invests between $1-3M into startups seeking seed round funding. The fund invests solely in the form of equity and is open to global investments within North America and Europe. 

The firm also serves as a Strategic Partner for its network of investors actively looking for curated investments that fit their criteria as a result provides capital raise support for life science companies in this regard. Investors in our networks are actively seeking companies in clinical development and can fund from $5M-$100M based on stage of development. 

In addition, the firm offers its strategic hub to provide innovative solutions to address many challenges they face. 
 
The firm invests primarily in therapeutic companies. The firm is opportunistic with regards to indication and open to investment opportunities within CNS, chronic diseases, rare diseases, and oncology. The firm invests in companies using tissue engineering/ tissue remediation modalities. For investment opportunities outside of therapeutics, such as SAAS companies or digital health platforms, the firm can connect startups with their investment network. 
 
The firm does not have any strict company/ management team requirements. The firm is open to global investment opportunities and prefers these international investments to seek distribution rights within the US. The firm typically does not seek a board seat on their investments, as they largely prefer to co-invest and do not lead rounds. The firm prefers management teams with previous exits/ experience. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A $400 million strategic corporate venture capital funded by a full-fledged oncology pharmaceutical company headquartered in Japan seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The firm will also consider the option-type of investments and spin-outs, in addition to pure equity investments. The fund is currently seeking opportunities in the USA, Europe and Japan, the focus being mainly in the US and Europe.

The firm will consider early-stage (generally research to pre-IND) first-in-class/new biology-based approaches in drug discovery and innovative platform technologies for drug discovery, especially assets that have a strategic angle to TPC’s pipeline. The firm considers a wide variety of modalities (biologics/oncolytic viruses and small molecules) as well as cell and gene therapy on an opportunistic basis. The firm’s primary indication of interest is oncology, but the firm is also interested in immunology, allergy, musculoskeletal, and orphan indications.

While the firm is primarily focused on therapeutics, the firm may review technologies in medical device, diagnostic, or digital health sectors on a very selective basis if there is a strong strategic alignment.

The firm is looking for teams with strong sector expertise. With the support of the parent corporation’s established expertise in the field of oncology product discovery and development, the firm will provide financial resources and company outreach to build strategic alliances to help translate novel research and high potential drug candidates into cornerstone products. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.